Financial Performance - The company's revenue for Q1 2022 was ¥130,918,431.95, a decrease of 22.16% compared to ¥168,185,663.92 in the same period last year[3] - Net profit attributable to shareholders was ¥31,165,938.51, down 24.22% from ¥41,125,705.42 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥22,220,408.33, reflecting a significant decline of 45.40% compared to ¥40,695,309.18 in the previous year[3] - Basic and diluted earnings per share were both ¥0.231, a decrease of 43.24% from ¥0.407 in the previous year[3] - The operating profit for Q1 2022 was CNY 36,844,806.34, down from CNY 49,956,751.65 in the same period last year, reflecting a decline of 26.2%[24] - The company reported a basic and diluted earnings per share of CNY 0.231 for Q1 2022, down from CNY 0.407 in Q1 2021, representing a decrease of 43.3%[25] Cash Flow and Assets - The net cash flow from operating activities increased by 840.96%, reaching ¥23,119,604.44, compared to a negative cash flow of -¥3,120,228.75 in the same period last year[3] - The total current assets amounted to CNY 2.28 billion, slightly down from CNY 2.29 billion at the beginning of the year[20] - The total liabilities were CNY 185.43 million, a decrease from CNY 216.51 million at the beginning of the year[21] - The company’s total assets stood at CNY 2.63 billion, showing a slight increase from CNY 2.63 billion at the beginning of the year[21] - The total cash and cash equivalents at the end of Q1 2022 were CNY 155,194,793.33, a decrease from CNY 1,860,005,090.28 at the beginning of the period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,640[11] - Jiangyin Hualan Electromechanical Technology Co., Ltd. holds 21.00% of shares, totaling 28,280,000 shares[12] - Huaxia Life Insurance Co., Ltd. owns 16.30% of shares, amounting to 21,956,522 shares[12] - The top ten shareholders collectively hold significant stakes, with the largest shareholder holding over 21%[12] - The total number of restricted shares at the end of the period is 103,125,403 shares[16] - The company plans to release 27,500 restricted shares on a specified date[16] - The company has a total of 18,054,262 shares under lock-up until November 1, 2022[16] - The company has no preferred shareholders as of the reporting period[14] - The company has a clear strategy for shareholder management, with specific release dates for restricted shares[15] - The company maintains a diverse shareholder base, including both institutional and individual investors[12] Investment and Strategy - The company reported a significant increase in cash management products, with trading financial assets rising to ¥1,518,485,188.89, a 100% increase[7] - The company received a tax refund of ¥1,830,806.52, marking a 100% increase compared to the previous year[10] - Investment cash outflow for cash management products was ¥1,812,000,000.00, indicating a significant investment strategy shift[10] - The company plans to continue its long-term strategies, focusing on automation and intelligent factory transformation projects[17] - The company aims to expand the production capacity of pre-filled medical packaging materials and enhance its technological reserves[17] Research and Development - Research and development expenses for the period were CNY 9.24 million, up from CNY 7.19 million in the previous year[23] Operating Expenses - The total operating expenses for Q1 2022 were CNY 136,948,208.16, compared to CNY 145,808,895.39 in Q1 2021, indicating a reduction of 6.1%[27] Other Financial Metrics - The cash flow from investing activities showed a net outflow of CNY -1,727,470,246.32, compared to CNY -12,273,086.57 in the same period last year[28] - The company reported a significant decrease in cash and cash equivalents, with a balance of CNY 175.10 million compared to CNY 1.87 billion at the beginning of the year[19] - The company did not conduct any audited financial reporting for Q1 2022[29]
华兰股份(301093) - 2022 Q1 - 季度财报